The Rational Use of Complement Inhibitors in Kidney Diseases.

Fiche du document

Types de document
Périmètre
Langue
Identifiants
Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ekir.2022.02.021

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/35685323

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/2468-0249

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_6B98D384D8F52

Licences

info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/




Citer ce document

F. Fakhouri et al., « The Rational Use of Complement Inhibitors in Kidney Diseases. », Serveur académique Lausannois, ID : 10.1016/j.ekir.2022.02.021


Métriques


Partage / Export

Résumé 0

The development of complement inhibitors represented one of the major breakthroughs in clinical nephrology in the last decade. Complement inhibition has dramatically transformed the outcome of one of the most severe kidney diseases, the atypical hemolytic uremic syndrome (aHUS), a prototypic complement-mediated disorder. The availability of complement inhibitors has also opened new promising perspectives for the management of several other kidney diseases in which complement activation is involved to a variable extent. With the rapidly growing number of complement inhibitors tested in a rapidly increasing number of indications, a rational use of this innovative and expensive new therapeutic class has become crucial. The present review aims to summarize what we know, and what we still ignore, regarding complement activation and therapeutic inhibition in kidney diseases. It also provides some clues and elements of thoughts for a rational approach of complement modulation in kidney diseases.

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Sur les mêmes disciplines

Exporter en